Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Asset Writedowns and Impairment (2025)

Historic Asset Writedowns and Impairment for Ascendis Pharma A (ASND) over the last 1 years, with Q1 2025 value amounting to $7.9 million.

  • Ascendis Pharma A's Asset Writedowns and Impairment changed N/A to $7.9 million in Q1 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year change of. This contributed to the annual value of $8.4 million for FY2023, which is N/A changed from last year.
  • Latest data reveals that Ascendis Pharma A reported Asset Writedowns and Impairment of $7.9 million as of Q1 2025.
  • In the past 5 years, Ascendis Pharma A's Asset Writedowns and Impairment registered a high of $7.9 million during Q1 2025, and its lowest value of $7.9 million during Q1 2025.